Examples of treatments under study:

• New chemotherapies, which are currently not very numerous
• New antibodies against the CD20 antigen, especially obinotuzumab or GA101
• Antibodies associated with toxins, also called immunotoxins or immunoconjugates.
• Histone deacetylase inhibitors (HDAC), which are medicines that act on the genetic material structure and are being studied especially for T-cell lymphomas (romidepsin in particular)
• Targeted therapies that act on the abnormal mechanisms of the lymphoma cells (certain targeted therapies, such as bortezomib, are already used for other blood diseases)
• Immunomodulatory medicines, such as lenalidomide, which is already frequently used against myelomas and which could act alone or combined with chemotherapy or rituximab for certain types of lymphoma.